Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors
Menée à partir des données des registres américains des cancers et de la base Medicare portant sur des patients âgés de plus de 66 ans et ayant survécu à un cancer (12 859 cas de cancers du sein, 17 329 cas de cancers du côlon et 4 427 cas de cancers du rectum), cette étude de cohorte rétrospective analyse le risque de récidive tardive (5 à 10 ans après le diagnostic)
Background: A growing population of older adult cancer survivors faces competing cancer and non-cancer health risks. There are limited real-world data on recurrence patterns beyond five years post-treatment.
Methods: This was a SEER-Medicare retrospective cohort study of patients aged ≥66 with stage I-III breast, colon, or rectal cancer who received definitive surgery and survived ≥5 years from diagnosis without recurrence or second primary malignancy. Late recurrence (5-10 years post-diagnosis) was identified using a validated algorithm to detect treated recurrence in Medicare claims. Demographic and clinical characteristics collected at cancer diagnosis were assessed as predictors of late treated recurrence using restricted mean survival time (RMST) regression.
Results: The sample included 12,859 breast, 17,329 colon, and 4,427 rectal cancer survivors. The cumulative incidence of late treated recurrence 5-10 years post-diagnosis was 5.0% in breast, 4.4% in colon, and 8.0% in rectal cancer survivors. In all cohorts, stage was associated with shorter RMST. The absolute risk difference between stage I and III was greatest in breast (2.% vs 18.1%), followed by rectal (5.2% vs. 10.3%) and colon (2.7% vs 6.7%) cancer survivors (P < .001 for all cohorts). Though their effect on RMST was modest (<5%), higher grade, node-positive, and ER-positive disease in breast, left-sided tumors in colon, and radiation in rectal cancer were associated with late treated recurrence. Across all cohorts, the incidence of other-cause mortality (24.1%-34.0%) exceeded cancer-specific mortality (2.9%-6.2%).
Conclusions: Late treated recurrence in older long-term survivors is uncommon, but risk remains elevated 5 years post-diagnosis in those with more advanced stage.
JNCI Cancer Spectrum , résumé, 2026